

Michael E. Cox, CFA, Sr Research Analyst
612 303-2043, michael.e.cox@pjc.com
Piper Jaffray & Co.

Reason for Report:

Company Update

Changes	Previous	Current
Rating	--	Overweight
Price Tgt	--	\$12.00
FY11E Rev (mil)	--	\$121.7
FY12E Rev (mil)	--	\$160.1
FY11E EPS	--	(\$0.13)
FY12E EPS	--	\$0.16

Price:	\$8.11
52 Week High:	\$14.98
52 Week Low:	\$6.88
12-Month Price Target:	\$12.00

Based on 3x EV/2011 sales

Shares Out (mil):	39.0
Market Cap. (mil):	\$316.3
Avg Daily Vol (000):	87
Book Value/Share:	\$3.00
Net Cash Per Share:	\$2.90
Debt to Total Capital:	0%
Div (ann):	\$0.00
Est LT EPS Growth:	25%
P/E to LT EPS Growth (FY11):	NA
Est Next Rep Date:	11/10/2010
Fiscal Year End:	Dec

Rev (mil)	2010E	2011E	2012E
Mar	\$25.7A	\$28.0E	\$36.5E
Jun	\$24.5A	\$32.0E	\$41.4E
Sep	\$21.7E	\$30.3E	\$40.7E
Dec	<u>\$25.3E</u>	<u>\$31.4E</u>	<u>\$41.6E</u>
FY	\$97.2E	\$121.7E	\$160.1E
CY	\$97.2E	\$121.7E	\$160.1E

FY RM	3.3x	2.6x	2.0x
CY RM	3.3x	2.6x	2.0x

EPS	2010E	2011E	2012E
Mar	(\$0.04)A	(\$0.04)E	\$0.01E
Jun	(\$0.15)A	(\$0.01)E	\$0.03E
Sep	(\$0.14)E	(\$0.06)E	\$0.06E
Dec	<u>(\$0.08)E</u>	<u>(\$0.03)E</u>	<u>\$0.06E</u>
FY	(\$0.40)E	(\$0.13)E	\$0.16E
CY	(\$0.40)E	(\$0.13)E	\$0.16E

FY P/E	NM	NM	50.7x
--------	----	----	-------

CY P/E	NM	NM	50.7x
--------	----	----	-------

EPS assumes post-IPO share count of 34.2mil basic / 39.0mil diluted.

Codexis, Inc. Overweight

(CDXS - \$8.11)

Incremental Positives: Takeaways on Biofuels & Carbon from Management Meetings

CONCLUSION:

We are reiterating our Overweight rating on shares of CDXS following investor meetings we held with management. We came away with incrementally more confidence that regulatory hurdles in the Shell/Cosan JV will be cleared and a partner in carbon adsorption will be announced by year end, providing a clearer path to market opportunities - though exact timing has not yet been articulated. Risk aversion and a desire for liquidity stocks have recently weighed on CDXS shares, but we believe 1.7x EV/FY11E revenue represents an attractive entry point.

- **Biofuels commercialization revenues more tangible under Shell/Cosan JV.**

We believe Codexis has four distinct revenue opportunities under the proposed JV. In 2012, a cost-reducing commercial-scale yeast could be introduced into the 23 Brazilian plants currently used to produce over 450 million gallons of ethanol annually. Codexis could also develop biocatalysts that produce higher-value chemicals, or supply potent enzyme cocktails for cellulosic ethanol using sugarcane residues. The fourth potential opportunity from the JV may be biocatalyst development for the production of diesel fuels.

- **Visibility into revenues from nascent carbon capture platform could present upside.**

Codexis' carbon capture platform may get a boost from the announcement of a large partner - which we liken to the biofuels relationship Codexis has with Shell - before the end of the year. The nascent carbon capture business has been heavily discounted, in our view, because it has yet to recognize revenues and the timing of carbon markets in the U.S. is likely highly sensitive to Congressional action. Despite these risks, we believe power utilities in the U.S. are readying themselves to be positioned for regulated carbon markets.

- **Pharmaceuticals business poised for 40% - 60% growth in 2010, with positive outlook.**

Codexis sells enzymes and active pharmaceutical ingredients for use in 35 products in its pharma business to improve yields, enhance chiral selectivity, and reduce production costs. Six drugs in the pipeline are marketed today. Partnerships with innovators have reshaped the pharma platform, where adaptation of their products or processes presents an annuitized revenue stream.

- **Maintain Overweight rating and \$12 price target.**

CDXS shares have underperformed as investors seek liquid names and select companies with more established cash flow over those incurring operating losses. We believe developments with Shell/Cosan and the carbon capture platform will be catalysts for the stock. Our price target remains \$12 (based on 3x EV/FY11 revenue).

INVESTMENT RECOMMENDATION:

The recent pullback in CDXS shares has improved the risk/reward profile and as commercialization catalysts approach, we believe valuations will expand.

RISKS TO ACHIEVEMENT OF TARGET PRICE:

Facility construction delays, reduced regulatory support for biofuels, competing bio-catalysis technologies, a sustained drop in oil prices

COMPANY DESCRIPTION:

Codexis custom-tailors enzymes that enhance the efficiency - and lower the cost - of producing pharmaceuticals, biofuels, and various other bio-based chemicals.

Piper Jaffray does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decisions. This report should be read in conjunction with important disclosure information, including an attestation under Regulation Analyst certification, found on pages 7 - 9 of this report or at the following site: <http://www.piperjaffray.com/researchdisclosures>.

We are reiterating our Overweight rating on shares of CDXS following investor meetings we held with management. We came away from the meetings with incrementally more confidence that any remaining regulatory hurdles in the proposed JV between Shell and Cosan will be cleared by year end, providing a clearer path to biofuels market opportunities for Codexis in biofuels. Also by the end of the year, we believe that Codexis will announce a large carbon absorption partner, with whom they are currently having advanced negotiations. Although exact timelines have not yet been articulated by management, we believe commercialization plans in biofuels from the Shell/Cosan JV and visibility into potential revenues from carbon capture present catalysts for the stock in the next 3-4 months. The investment environment of relative risk aversion and a desire for highly liquid stocks have recently weighed on CDXS shares. We believe that the current valuation of 1.7x EV/FY11E revenue represents an attractive entry point.

Biofuels commercialization revenues more tangible under Shell/Cosan JV. We believe Codexis has four revenue opportunities under the proposed JV. In 2012, Codexis could begin to introduce optimized strains of yeast for use in the 23 Brazilian plants currently used to produce over 450 million gallons of ethanol annually. The optimized yeasts could reduce costs in the production of first-generation ethanol representing a rapid path to commercial revenues, for which Codexis would earn a few pennies per gallon in royalties. Additionally, Codexis would have the opportunity to develop biocatalysts that produce higher-value chemicals, such as polymer intermediates and solvents, rather than ethanol. Such an application of the Codexis technology could be deployed by 2013. The third potential opportunity comes through the production of highly productive enzymes for cellulosic ethanol using sugarcane residues – namely bagasse, which is burned for electricity or landfilled, and the tops and leaves, which are currently burned in the field. The fourth potential opportunity to come from the JV could be biocatalyst development for the production of diesel fuels primarily for the European markets.

Visibility into revenues from nascent carbon capture platform could present upside. Codexis' carbon capture platform may get a boost from the announcement of a large partner – which we liken to the biofuels relationship Codexis has with Shell – before the end of the year. The nascent carbon capture business has been heavily discounted, in our view, because it has yet to recognize revenues and the timing of carbon markets in the U.S. is likely highly sensitive to Congressional action. Despite these risks, we believe power utilities in the U.S. are readying themselves to be positioned for regulated carbon markets.

Pharmaceuticals business poised for 40% - 60% growth in 2010, with positive outlook. Codexis sells either enzymes or active pharmaceutical ingredients for use in 35 products in its pharmaceutical business to improve yields, enhance chiral selectivity, and thereby reduce production costs. Six pharmaceuticals of the 35 in the pipeline are marketed today including Lipitor (atorvastatin) and the type II diabetes drug Januvia (sitagliptin) which Merck expects to be a \$3 billion drug this year. Other significant opportunities in the pharmaceutical market include the hepatitis C drug telaprevir with partner Vertex. Partnerships with the larger innovators has reshaped the way Codexis approaches the pharma market, where adaptation of one of their products or processes presents an annuitized revenue stream.

Maintain Overweight rating and \$12 price target. CDXS shares have underperformed as investors seek highly liquid names and tend to select companies with more established operational cash flow over those incurring operating losses. We believe positive developments in the Shell/Cosan JV and the carbon capture platform will act as catalysts for the stock. Our price target remains \$12 (based on 3x EV/FY11E revenue) with \$2.90 in cash and FY11E revenues of \$121.7 million.

Codexis

Income Statement

(\$ In Million Except Per Share Data)

Date: 9/14/10

Price: \$8.11

Current disclosure information for this company can be found at:

<http://www.piperjaffray.com/researchdisclosures>

	2010E				2011E				2012E				FY09	FY10E	2011E	2012E
	1QA	2QA	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q				
	Mar	June	Sept	Dec	Mar	June	Sept	Dec	Mar	June	Sept	Dec				
Net Sales	25.7	24.5	21.7	25.3	28.0	32.0	30.3	31.4	36.5	41.4	40.7	41.6	82.9	97.2	121.7	160.1
Cost of Sales	5.2	6.1	5.0	5.7	6.8	9.5	7.4	7.5	10.9	14.1	12.0	12.0	16.7	22.0	31.2	48.9
Gross Profit	20.5	18.4	16.8	19.5	21.2	22.5	22.9	24.0	25.6	27.3	28.7	29.7	66.2	75.2	90.5	111.2
Research & development	13.0	13.0	13.2	13.5	13.5	14.0	15.0	15.0	15.0	16.0	16.0	16.5	45.9	52.7	57.5	63.5
Operations	2.0	2.0	2.0	2.0	2.0	2.0	2.5	2.5	2.5	2.5	3.0	3.0	8.9	8.0	9.0	11.0
SG&A	6.6	6.7	6.5	7.0	7.5	7.5	8.0	8.0	8.0	8.0	8.0	8.5	29.9	26.8	31.0	32.5
Operating Income from operations	(1.100)	(3.3)	(4.9)	(3.0)	(1.8)	(1.0)	(2.6)	(1.5)	0.1	0.8	1.7	1.7	(18.4)	(12.3)	(7.0)	4.2
Interest Expense, net	(0.3)	(0.6)	-	-	0.4	0.4	0.4	0.4	0.5	0.5	0.5	0.5	(1.2)	(0.9)	1.6	2.0
Other	-	-	-	-	-	-	-	-	-	-	-	-	(0.6)	-	-	-
Total Other Income (loss)	(0.3)	(0.6)	-	-	0.4	0.4	0.4	0.4	0.5	0.5	0.5	0.5	(1.9)	(0.9)	1.6	2.0
Pretax Income	(1.4)	(3.9)	(4.9)	(3.0)	(1.4)	(0.6)	(2.2)	(1.1)	0.6	1.3	2.2	2.2	(20.2)	(13.2)	(5.4)	6.2
Tax Provision	0.1	(0.1)	0.2	0.2	0.2	0.2	0.2	0.2	-	-	-	-	(0.1)	0.3	0.8	-
Net Income	(1.4)	(3.9)	(4.8)	(2.8)	(1.2)	(0.4)	(2.0)	(0.9)	0.6	1.3	2.2	2.2	(20.3)	(12.9)	(4.6)	6.2
Shares Basic	34.2	26.6	34.2	34.2	34.2	34.2	34.2	34.2	34.2	34.2	34.2	34.2	34.2	32.3	34.2	34.2
Shares Diluted (Mils.)	39.0	39.0	39.0	39.0	39.0	39.0	39.0	39.0	39.0	39.0	39.0	39.0	39.0	39.0	39.0	39.0
EPS-Reported Diluted	(\$0.04)	(\$0.15)	(\$0.14)	(\$0.08)	(\$0.04)	(\$0.01)	(\$0.06)	(\$0.03)	\$0.01	\$0.03	\$0.06	\$0.06	(\$0.59)	(\$0.40)	(\$0.13)	\$0.16
Depreciation and amortization	\$1.8	\$2.2	\$2.1	\$2.1	\$2.4	\$2.4	\$2.4	\$2.4	\$3.8	\$3.8	\$3.8	\$3.8	\$6.1	\$8.3	\$9.5	15.0
Non-cash stock comp & other	\$2.0	\$2.5	\$1.5	\$1.5	\$2.1	\$2.1	\$2.1	\$2.1	\$1.9	\$1.9	\$1.9	\$1.9	\$4.9	\$7.5	\$8.5	7.5
EBITDA	\$2.8	\$1.4	(\$1.3)	\$0.6	\$2.7	\$3.5	\$1.9	\$3.0	\$5.7	\$6.5	\$7.3	\$7.3	(\$7.3)	\$3.5	\$11.0	26.7
Margins:																
Gross Margin	79.7%	75.2%	77.1%	77.3%	75.6%	70.2%	75.6%	76.2%	70.1%	66.0%	70.5%	71.3%	79.9%	77.3%	74.4%	69.5%
R&D expense ratio	50.5%	53.1%	60.7%	53.4%	48.2%	43.8%	49.5%	47.7%	41.1%	38.7%	39.4%	39.7%	55.3%	54.2%	47.2%	39.7%
Operations expense ratio	7.8%	8.2%	9.2%	7.9%	7.1%	6.3%	8.3%	8.0%	6.9%	6.0%	7.4%	7.2%	10.7%	8.2%	7.4%	6.9%
SG&A expense ratio	25.7%	27.2%	29.9%	27.7%	26.8%	23.4%	26.4%	25.4%	21.9%	19.3%	19.7%	20.4%	36.0%	27.5%	25.5%	20.3%
EBITDA Margin	10.7%	5.6%	-6.1%	2.6%	9.5%	10.9%	6.3%	9.4%	15.6%	15.6%	17.9%	17.5%	-8.8%	3.6%	9.1%	16.7%
Operating Margin	-4.3%	-13.3%	-22.8%	-11.8%	-6.6%	-3.2%	-8.5%	-4.9%	0.2%	2.0%	4.1%	4.0%	-22.2%	-12.6%	-5.7%	2.6%
Pretax Margin	-5.6%	-15.8%	-22.8%	-11.8%	-5.2%	-1.9%	-7.2%	-3.6%	1.5%	3.2%	5.3%	5.2%	-24.4%	-13.6%	-4.4%	3.9%
Net Income Margin	-5.3%	-16.1%	-22.1%	-11.2%	-4.4%	-1.3%	-6.5%	-3.0%	1.5%	3.2%	5.3%	5.2%	-24.5%	-13.3%	-3.8%	3.9%

Codexis

Segment Sales & Profit Analysis

(\$ In Thousands Except Per Share Data)

	2010E				2011E				2012E							
	1QA	2QA	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q				
	Mar	June	Sept	Dec	Mar	June	Sept	Dec	Mar	June	Sept	Dec	FY09	FY10E	2011E	2012E
Revenue																
Pharma	6.9	8.5	6.7	7.8	10.2	14.2	11.0	11.2	17.0	22.0	18.7	18.7	20.0	29.9	46.6	76.4
Generic	2.4	4.2	2.4	3.6	3.9	7.2	4.1	4.5	5.1	8.6	4.9	5.5	8.8	12.7	19.8	24.1
Innovator	4.5	4.3	4.3	4.1	6.3	7.0	6.9	6.6	12.0	13.3	13.8	13.2	11.2	17.2	26.8	52.3
Biofuels	16.0	15.5	15.0	17.5	17.0	17.0	18.5	19.5	17.7	17.7	19.2	20.2	62.8	64.1	72.2	74.9
FTE	14.5	14.7	13.5	13.5	15.5	15.5	15.5	15.5	16.2	16.2	16.2	16.2	53.5	56.2	62.2	64.9
Other/Milestones	1.5	0.9	1.5	4.0	1.5	1.5	3.0	4.0	1.5	1.5	3.0	4.0	9.3	7.9	10.0	10.0
Bio-industrials	0.0	0.0	0.0	0.0	0.5	0.5	0.5	0.5	1.0	1.0	2.0	2.0	0.1	0.0	2.0	6.0
Carbon	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	1.0	0.0	0.0	0.0	2.0
Water, Other	0.0	0.0	0.0	0.0	0.5	0.5	0.5	0.5	1.0	1.0	1.0	1.0	0.1	0.0	2.0	4.0
Grants	<u>2.7</u>	<u>0.5</u>	<u>0.0</u>	<u>0.0</u>	<u>0.3</u>	<u>0.3</u>	<u>0.3</u>	<u>0.3</u>	<u>0.7</u>	<u>0.7</u>	<u>0.7</u>	<u>0.7</u>	0.0	3.2	1.0	2.8
TOTAL	25.7	24.5	21.7	25.3	28.0	32.0	30.3	31.4	36.5	41.4	40.7	41.6	82.9	97.2	121.7	160.1
Revenue % Change																
Pharma	39.4%	82.2%	33.0%	46.8%	47.0%	67.5%	63.6%	43.6%	67.1%	54.5%	70.1%	67.4%		49.7%	55.7%	64.0%
Generic	30.0%	157.4%	50.0%	0.0%	60.0%	70.0%	70.0%	25.0%	30.0%	20.0%	20.0%	20.0%		45.1%	55.2%	22.0%
Innovator	45.0%	41.1%	25.0%	150.0%	40.0%	65.0%	60.0%	60.0%	90.0%	90.0%	100.0%	100.0%		53.3%	56.0%	95.0%
Biofuels	11.2%	6.6%	0.0%	-7.1%	6.2%	9.9%	23.6%	11.6%	4.0%	4.0%	3.7%	3.5%		2.0%	12.7%	3.8%
FTE	12.2%	8.4%	0.2%	-0.5%	6.9%	6.0%	15.1%	15.1%	4.4%	4.4%	4.4%	4.4%		5.0%	10.6%	4.4%
Other/Milestones	2.9%	-16.6%	-1.4%	-24.1%	0.0%	76.3%	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%		-15.3%	27.4%	0.0%
Bio-industrials	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a		n/a	n/a	n/a
Grants	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a		n/a	n/a	n/a
Total	32.4%	27.5%	8.3%	4.3%	8.9%	30.7%	39.4%	24.4%	30.3%	29.3%	34.2%	32.3%		17.2%	25.3%	31.5%
Gross Profit																
Pharma	1.719	2.409	1.750	2.020	3.366	4.689	3.634	3.682	6.135	7.906	6.743	6.723	3.310	7.899	15.371	27.51
Biofuels	16.041	15.504	15.004	17.504	17.039	17.039	18.539	19.539	17.729	17.729	19.229	20.229	62.806	64.053	72.156	74.92
Bio-industrials	0.000	0.000	0.000	0.000	0.500	0.500	0.500	0.500	1.000	1.000	2.000	2.000	0.069	0.000	2.000	6.00
Grants	<u>2.722</u>	<u>0.492</u>	<u>0.000</u>	<u>0.000</u>	<u>0.250</u>	<u>0.250</u>	<u>0.250</u>	<u>0.250</u>	<u>0.700</u>	<u>0.700</u>	<u>0.700</u>	<u>0.700</u>	0.046	3.214	1.000	2.80
TOTAL	20.482	18.405	16.754	19.524	21.155	22.478	22.924	23.971	25.564	27.335	28.672	29.652	66.230	75.166	90.528	111.22
Gross Margins																
Pharma	24.8%	28.4%	26.0%	26.0%	33.0%	33.0%	33.0%	33.0%	36.0%	36.0%	36.0%	36.0%	16.6%	26.4%	33.0%	36.0%
Biofuels	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a				
Bio-industrials	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a				
Grants	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a				
Total	79.7%	75.2%	77.1%	77.3%	75.6%	70.2%	75.6%	76.2%	70.1%	66.0%	70.5%	71.3%	79.9%	77.3%	74.4%	69.5%


Codexis
Balance Sheet

(\$ Million)	FY10E				FY11E				FY12E				Fiscal	Fiscal	Fiscal	Fiscal	Fiscal
	Q1A	Q2A	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	2008	2009E	2010E	2011E	2012E
Cash	29.2	100.3	99.2	95.6	93.5	91.7	88.4	83.4	79.0	76.5	74.9	73.4	37.1	55.6	95.6	83.4	73.4
Other current assets	21.5	14.3	16.0	17.7	20.9	23.6	25.5	28.2	30.1	31.3	32.7	33.8	11.2	11.8	17.7	28.2	33.8
Current Assets	50.7	114.6	115.1	113.3	114.4	115.3	113.9	111.5	109.2	107.8	107.5	107.2	48.3	67.4	113.3	111.5	107.2
Plant/Property/Equipment (Net)	21.3	21.3	22.2	23.1	23.7	24.3	26.0	27.6	34.8	42.1	49.3	56.6	16.0	21.6	23.1	27.6	56.6
Other long-term assets	11.9	7.8	17.8	22.8	27.8	27.8	27.8	27.8	17.8	7.8	7.8	7.8	6.5	10.1	22.8	27.8	7.8
TOTAL ASSETS	83.8	143.7	155.1	159.2	165.9	167.4	167.6	166.9	161.8	157.7	164.7	171.6	70.9	99.0	159.2	166.9	171.6
Current liabilities:																	
Notes Payable	-	-	-	-	-	-	-	-	-	-	-	-	5.2	7.9	-	-	-
Deferred revenue	9.4	4.6	8.9	9.0	9.2	9.9	10.7	10.1	10.8	11.6	12.4	13.3	10.6	24.7	9.0	10.1	13.3
Other Current Liabilities	28.0	26.3	26.7	27.0	27.7	26.8	26.0	24.7	26.4	28.3	30.4	32.4	26.6	31.5	27.0	24.7	32.4
Total Current Liabilities:	37.4	30.8	35.6	36.0	36.8	36.6	36.7	34.8	37.2	39.9	42.8	45.7	42.4	64.2	36.0	34.8	45.7
Long-Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	8.5	-	-	-	-
Other liabilities	10.9	8.5	20.0	26.5	33.7	35.8	37.9	40.0	31.9	23.8	25.7	27.5	16.4	-	26.5	40.0	27.5
Total Liabilities	48.3	39.4	55.6	62.5	70.5	72.4	74.6	74.8	69.1	63.7	68.5	73.3	67.3	64.2	62.5	74.8	73.3
Preferred stock	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stockholders' equity	35.5	104.3	99.5	96.7	95.4	95.0	93.0	92.1	92.7	94.0	96.2	98.3	3.6	34.8	96.7	92.1	98.3
TOTAL LIABILITIES & S.E.	83.8	143.7	155.1	159.2	165.9	167.4	167.6	166.9	161.8	157.7	164.7	171.6	70.9	99.0	159.2	166.9	171.6

Codexis
Statement of Cash Flow

(\$ Millions)	FY10E				FY11E				FY12E				Fiscal	Fiscal	Fiscal	Fiscal	Fiscal
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	2008	2009	2010E	2011E	2012E
Operating:																	
Net Income	(1.4)	(3.9)	(4.8)	(2.8)	(1.2)	(0.4)	(2.0)	(0.9)	0.6	1.3	2.2	2.2	(45.1)	(20.3)	(12.9)	(4.6)	6.2
Depreciation/Amortization	1.8	1.9	2.1	2.1	2.4	2.4	2.4	2.4	3.8	3.8	3.8	3.8	4.6	7.8	8.0	9.5	15.0
Share-based compensation	1.7	2.3	1.5	1.5	2.1	2.1	2.1	2.1	1.9	1.9	1.9	1.9	3.5	4.8	7.0	8.5	7.5
Changes in operating assets and liabilities:	(14.1)	(6.9)	3.0	(1.4)	(2.3)	(2.9)	(1.8)	(4.6)	0.5	1.5	1.6	1.7	0.8	(1.0)	(19.4)	(11.6)	5.3
Net Cash Flow for Operating Activities	(12.0)	(6.7)	1.9	(0.6)	1.0	1.2	0.7	(1.0)	6.6	8.4	9.4	9.5	(36.3)	(8.7)	(17.4)	1.8	34.0
Investing:																	
Purchases of plant, property, equipment	(1.3)	(1.9)	(3.0)	(3.0)	(3.0)	(3.0)	(4.0)	(4.0)	(11.0)	(11.0)	(11.0)	(11.0)	(8.5)	(10.8)	(9.2)	(14.0)	(44.0)
Other	13.6	(39.0)	-	-	-	-	-	-	-	-	-	-	15.6	(0.4)	(25.4)	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-	-	-	-	(1.3)	-	-	-
Net Investing Cash Flow	12.3	(40.9)	(3.0)	(3.0)	(3.0)	(3.0)	(4.0)	(4.0)	(11.0)	(11.0)	(11.0)	(11.0)	7.1	(12.5)	(34.6)	(14.0)	(44.0)
Financing:																	
Net change in long-term debt	(1.3)	(1.3)	-	-	-	-	-	-	-	-	-	-	(4.3)	(6.1)	(2.7)	-	-
Issuance of equity/preferred	-	72.7	-	-	-	-	-	-	-	-	-	-	0.4	-	-	-	-
Other	(1.5)	(1.5)	-	-	-	-	-	-	-	-	-	-	-	0.1	(3.0)	-	-
Net cash provided by Financing Activities	(2.8)	69.8	-	-	-	-	-	-	-	-	-	-	(3.9)	(6.0)	(5.6)	-	-
Exchange rate changes	(0.0)	(0.0)															
Increase in cash and cash equivalents	(2.6)	22.3	(1.1)	(3.6)	(2.0)	(1.8)	(3.3)	(5.0)	(4.4)	(2.6)	(1.6)	(1.5)		(27.2)	(57.7)	(12.2)	(10.0)
Cash at beginning of period	55.9	53.4	75.6	74.5	70.9	68.8	67.0	63.7	58.7	54.3	51.8	50.2		37.1	55.9	(1.8)	58.7
Cash at end of period	53.4	75.6	74.5	70.9	68.8	67.0	63.7	58.7	54.3	51.8	50.2	48.7		10.0	(1.8)	58.7	48.7
Free cash flow													(44.9)	(19.5)	(26.6)	(12.2)	(10.0)

Important Research Disclosures



Notes: The boxes on the Rating and Price Target History chart above indicate the date of the Research Note, the rating, and the price target. Each box represents a date on which an analyst made a change to a rating or price target, except for the first box, which may only represent the first Note written during the past three years.

Legend:

I: Initiating Coverage

R: Resuming Coverage

T: Transferring Coverage

D: Discontinuing Coverage

S: Suspending Coverage

OW: Overweight

N: Neutral

UW: Underweight

B: Buy (Piper Jaffray discontinued use of the B, N, and S ratings on June 30, 2009)

N: Neutral

S: Sell

OP: Outperform (Piper Jaffray discontinued use of the OP, MP and UP ratings on November 15, 2007)

MP: Market Perform

UP: Underperform

AL On/AL Off: Placed on/removed from the Alpha List maintained by Piper Jaffray (AL use discontinued March 2010)

NA: Not Available

UR: Under Review

Distribution of Ratings/IB Services Piper Jaffray				
Rating	Count	Percent	IB Serv./Past 12 Mos.	
			Count	Percent
BUY [OW]	341	49.60	79	23.17
HOLD [N]	286	41.60	24	8.39
SELL [UW]	60	8.70	3	5.00

Note: Distribution of Ratings/IB Services shows the number of companies currently in each rating category from which Piper Jaffray and its affiliates received compensation for investment banking services within the past 12 months. FINRA rules require disclosure of which ratings most closely correspond with "buy," "hold," and "sell" recommendations. Piper Jaffray ratings are not the equivalent of buy, hold or sell, but instead represent recommended relative weightings. Nevertheless, Overweight corresponds most closely with buy, Neutral with hold and Underweight with sell. See Stock Rating definitions below.

Important Research Disclosures

Analyst Certification — Michael E. Cox, CFA, Sr Research Analyst

The views expressed in this report accurately reflect my personal views about the subject company and the subject security. In addition, no part of my compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in this report.

Research Disclosures

Piper Jaffray was making a market in the securities of Codexis, Inc. at the time this research report was published. Piper Jaffray will buy and sell Codexis, Inc. securities on a principal basis.

Piper Jaffray has received compensation for investment banking services from or has had a client relationship with Codexis, Inc. within the past 12 months.

Within the past 12 months Piper Jaffray was a managing underwriter of a public offering of, or dealer manager of a tender offer for, the securities of Codexis, Inc. or the securities of an affiliate.

Within the past 3 years Piper Jaffray participated in a public offering of, or acted as a dealer manager for, Codexis, Inc. securities.

Affiliate Disclosures: This report has been prepared by Piper Jaffray & Co. and/or its affiliates Piper Jaffray Ltd. and Piper Jaffray Asia Securities Limited, all of which are subsidiaries of Piper Jaffray Companies (collectively Piper Jaffray). Piper Jaffray & Co. is regulated by FINRA, NYSE, and the United States Securities and Exchange Commission, and its headquarters is located at 800 Nicollet Mall, Minneapolis, MN 55402. Piper Jaffray Ltd. is registered in England, no. 3846990, and its registered office is One South Place, London, EC2M 2RB. Piper Jaffray Ltd. is authorised and regulated by the UK Financial Services Authority ("FSA"), entered on the FSA's register, no. 191657 and is a member of the London Stock Exchange. Piper Jaffray Asia Securities Limited is a licensed corporation regulated by the Securities and Futures Commission of Hong Kong ("SFC"), entered on the SFC's register, no. ABO154, and is an exchange participant of The Stock Exchange of Hong Kong Limited. Its headquarters is located at 39/F Tower 1 Lippo Centre, 89 Queensway, Hong Kong. Disclosures in this section and in the Other Important Information section referencing Piper Jaffray include all affiliated entities unless otherwise specified.

Piper Jaffray research analysts receive compensation that is based, in part, on overall firm revenues, which include investment banking revenues.

Rating Definitions

Stock Ratings: Piper Jaffray ratings are indicators of expected total return (price appreciation plus dividend) within the next 12 months. At times analysts may specify a different investment horizon or may include additional investment time horizons for specific stocks. Stock performance is measured relative to the group of stocks covered by each analyst. Lists of the stocks covered by each are available at www.piperjaffray.com/researchdisclosures. Stock ratings and/or stock coverage may be suspended from time to time in the event that there is no active analyst opinion or analyst coverage, but the opinion or coverage is expected to resume. Research reports and ratings should not be relied upon as individual investment advice. As always, an investor's decision to buy or sell a security must depend on individual circumstances, including existing holdings, time horizons and risk tolerance. Piper Jaffray sales and trading personnel may provide written or oral commentary, trade ideas, or other information about a particular stock to clients or internal trading desks reflecting different opinions than those expressed by the research analyst. In addition, Piper Jaffray technical research products are based on different methodologies and may contradict the opinions contained in fundamental research reports.

- **Overweight (OW):** Anticipated to outperform relative to the median of the group of stocks covered by the analyst.
- **Neutral (N):** Anticipated to perform in line relative to the median of the group of stocks covered by the analyst.
- **Underweight (UW):** Anticipated to underperform relative to the median of the group of stocks covered by the analyst.

An industry outlook represents the analyst's view of the industry represented by the stocks in the analyst's coverage group. A Favorable industry outlook generally means that the analyst expects the fundamentals and/or valuations of the industry to improve over the investment time horizon. A Neutral industry outlook generally means that the analyst does not expect the fundamentals and/or valuations of the industry to either improve or deteriorate meaningfully from its current state. An Unfavorable industry outlook generally means that the analyst expects the fundamentals and/or valuations of the industry to deteriorate meaningfully over the investment time horizon.

Other Important Information

The material regarding the subject company is based on data obtained from sources we deem to be reliable; it is not guaranteed as to accuracy and does not purport to be complete. This report is solely for informational purposes and is not intended to be used as the primary basis of investment decisions. Piper Jaffray has not assessed the suitability of the subject company for any person. Because of individual client requirements, it is not, and it should not be construed as, advice designed to meet the particular investment needs of any investor. This report is not an offer or the solicitation of an offer to sell or buy any security. Unless otherwise noted, the price of a security mentioned in this report is the market closing price as of the end of the prior business day. Piper Jaffray does not maintain a predetermined schedule for publication of research and will not necessarily update this report. Piper Jaffray policy generally prohibits research analysts from sending draft research reports to subject companies; however, it should be presumed that the analyst(s) who authored this report has had discussions with the subject company to ensure factual accuracy prior to publication, and has had assistance from the company in conducting diligence, including visits to company sites and meetings with company management and other representatives.

This report is published in accordance with a conflicts management policy, which is available at <http://www.piperjaffray.com/researchdisclosures>.

Notice to customers: This material is not directed to, or intended for distribution to or use by, any person or entity if Piper Jaffray is prohibited or restricted by any legislation or regulation in any jurisdiction from making it available to such person or entity. Customers in any of the jurisdictions where Piper Jaffray and its affiliates do business who wish to effect a transaction in the securities discussed in this report should contact their local Piper Jaffray representative. **Europe:** This material is for the use of intended recipients only and only for distribution to professional and institutional investors, i.e. persons who are authorised persons or exempted persons within the meaning of the Financial Services and Markets Act 2000 of the United Kingdom, or persons who have been categorised by Piper Jaffray Ltd. as professional clients under the rules of the Financial Services Authority. **Asia:** This report is distributed in Hong Kong by Piper Jaffray Asia Securities Limited, which is regulated by the Hong Kong SFC. This report is intended only for distribution to professional investors as defined in the Hong Kong Securities and Futures Ordinance and is for the use of intended recipients only. **United States:** This report is distributed in the United States by Piper Jaffray & Co., member SIPC, FINRA and NYSE, Inc., which accepts responsibility for its contents. The securities described in this report may not have been registered under the U.S. Securities Act of 1933 and, in such case, may not be offered or sold in the United States or to U.S. persons unless they have been so registered, or an exemption from the registration requirements is available.

This report is produced for the use of Piper Jaffray customers and may not be reproduced, re-distributed or passed to any other person or published in whole or in part for any purpose without the prior consent of Piper Jaffray & Co. Additional information is available upon request.

Copyright 2010 Piper Jaffray. All rights reserved.